Lighthouse Investment Partners LLC Acquires Shares of 30,000 Structure Therapeutics Inc. (NASDAQ:GPCR)

Lighthouse Investment Partners LLC bought a new position in shares of Structure Therapeutics Inc. (NASDAQ:GPCR) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 30,000 shares of the company’s stock, valued at approximately $1,178,000. Lighthouse Investment Partners LLC owned 0.06% of Structure Therapeutics at the end of the most recent quarter.

Several other large investors also recently modified their holdings of GPCR. Sandia Investment Management LP purchased a new stake in Structure Therapeutics in the 2nd quarter worth approximately $39,000. Sectoral Asset Management Inc. purchased a new position in shares of Structure Therapeutics during the fourth quarter valued at about $139,000. ADAR1 Capital Management LLC bought a new position in Structure Therapeutics in the fourth quarter worth about $163,000. Mather Group LLC. purchased a new stake in Structure Therapeutics in the second quarter worth about $214,000. Finally, Sei Investments Co. purchased a new position in shares of Structure Therapeutics during the 2nd quarter worth approximately $212,000. 91.78% of the stock is owned by institutional investors.

Structure Therapeutics Price Performance

GPCR stock opened at $41.75 on Friday. Structure Therapeutics Inc. has a 1-year low of $26.61 and a 1-year high of $75.02. The stock has a market capitalization of $1.95 billion, a P/E ratio of -54.22 and a beta of -3.52. The business has a fifty day moving average price of $38.14 and a 200-day moving average price of $39.78.

Structure Therapeutics (NASDAQ:GPCR) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.05. As a group, analysts anticipate that Structure Therapeutics Inc. will post -0.86 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have recently commented on GPCR shares. Cantor Fitzgerald restated an “overweight” rating and issued a $65.00 target price on shares of Structure Therapeutics in a research note on Monday, September 23rd. Morgan Stanley assumed coverage on shares of Structure Therapeutics in a research note on Monday, September 23rd. They set an “overweight” rating and a $118.00 target price for the company. JMP Securities dropped their price target on Structure Therapeutics from $91.00 to $86.00 and set a “market outperform” rating on the stock in a research report on Friday, August 9th. Finally, BMO Capital Markets upped their price target on Structure Therapeutics from $83.00 to $100.00 and gave the stock an “outperform” rating in a research note on Friday, June 7th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Structure Therapeutics has a consensus rating of “Buy” and a consensus target price of $88.33.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.